| Identification | More | [Name]
4-Aminopiperidine | [CAS]
13035-19-3 | [Synonyms]
4-AMINOPIPERIDINE
4-PIPERIDINEAMINE
PIPERIDIN-4-YLAMINE
4-Amino
4-Aminopiperidine 97%
4-AMINOPIPERDINE 98+%
4-AMINO PIPERIDINE PIPERIDIN-4-YLAMINE
4-Piperidinamine
Piperidine-4-amine | [EINECS(EC#)]
1533716-785-6 | [Molecular Formula]
C5H12N2 | [MDL Number]
MFCD02179399 | [Molecular Weight]
100.16 | [MOL File]
13035-19-3.mol |
| Chemical Properties | Back Directory | [Melting point ]
25 °C | [Boiling point ]
65°C 18mm | [density ]
0.945 g/mL at 25 °C(lit.)
| [refractive index ]
n20/D 1.4910(lit.)
| [Fp ]
>230 °F
| [storage temp. ]
Keep in dark place,Inert atmosphere,2-8°C | [form ]
Powder | [pka]
10.37±0.20(Predicted) | [color ]
Off-white to yellow | [Sensitive ]
Hygroscopic | [BRN ]
1105 | [CAS DataBase Reference]
13035-19-3(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
C,Xi | [Risk Statements ]
R10:Flammable.
R34:Causes burns. | [Safety Statements ]
S16:Keep away from sources of ignition-No smoking .
S23:Do not breathe gas/fumes/vapor/spray (appropriate wording to be specified by the manufacturer) .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) .
S6:Keep under ... (inert gas to be specified by the manufacturer) . | [RIDADR ]
UN 2920 8/PG 2
| [WGK Germany ]
3
| [Hazard Note ]
Irritant | [HazardClass ]
3 | [PackingGroup ]
III | [HS Code ]
29333990 |
| Hazard Information | Back Directory | [Uses]
Reactant for synthesis of:
- Cdk5/p25 kinase inhibitors
- Antimalarials
- Selective cyclin-dependent kinase 4/6 inhibitors
- IKKβ inhibitors
- Orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation
- Human and murine soluble epoxide hydrolase inhibitors
| [Uses]
Reactant for synthesis of 4-Aminopiperidine:
- Cdk5/p25 kinase inhibitors
- Antimalarials
- Selective cyclin-dependent kinase 4/6 inhibitors
- IKKβ inhibitors
- Orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation
- Human and murine soluble epoxide hydrolase inhibitors
|
|